Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Phase 1 data may support continued research of amphiphile lymph node-targeted immunotherapy in solid tumors.

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.